BB
GILD icon

BB Biotech’s Gilead Sciences GILD Stock Holding History

BB Biotech’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$74.3M Sell
1,142,204
-190,000
-14% -$12.6M 1.87% 17
2018
Q4 		$83.3M Sell
1,332,204
-622,392
-32% -$43.5M 2.67% 14
2018
Q3 		$151M Sell
1,954,596
-420,000
-18% -$31.7M 3.99% 9
2018
Q2 		$168M Sell
2,374,596
-300,000
-11% -$21.2M 4.86% 8
2018
Q1 		$202M Sell
2,674,596
-100,000
-4% -$7.95M 5.57% 8
2017
Q4 		$199M Hold
2,774,596
– – 5.6% 6
2017
Q3 		$225M Hold
2,774,596
– – 6.22% 4
2017
Q2 		$196M Hold
2,774,596
– – 6% 5
2017
Q1 		$188M Hold
2,774,596
– – 6.16% 4
2016
Q4 		$199M Hold
2,774,596
– – 7.36% 4
2016
Q3 		$220M Hold
2,774,596
– – 7.72% 5
2016
Q2 		$231M Hold
2,774,596
– – 9.14% 3
2016
Q1 		$255M Hold
2,774,596
– – 10.13% 4
2015
Q4 		$281M Hold
2,774,596
– – 7.91% 4
2015
Q3 		$272M Buy
2,774,596
+59,000
+2% +$6.55M 8.64% 4
2015
Q2 		$318M Sell
2,715,596
-150,000
-5% -$16.4M 8.62% 4
2015
Q1 		$281M Sell
2,865,596
-80,000
-3% -$8.12M 8.38% 4
2014
Q4 		$278M Buy
2,945,596
+150,000
+5% +$15.5M 8.99% 4
2014
Q3 		$298M Sell
2,795,596
-692,900
-20% -$67.8M 12.1% 2
2014
Q2 		$289M Sell
3,488,496
-25,000
-0.7% -$1.95M 13.74% 2
2014
Q1 		$249M Sell
3,513,496
-34,218
-1% -$2.68M 12.83% 3
2013
Q4 		$266M Sell
3,547,714
-80,000
-2% -$5.57M 14.23% 2
2013
Q3 		$228M Sell
3,627,714
-72,286
-2% -$4.32M 12.41% 3
2013
Q2 		$190M Buy
+3,700,000
New +$193M 13.67% 3

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BB Biotech's GILD Position: Q1 2019 in Review

BB Biotech reduced its Gilead Sciences (GILD) stake by 14% in Q1 2019, selling an estimated $12.6M and leaving 1,142,204 shares worth $74.3M. The position accounts for 1.87% of the portfolio, ranked #17.

BB Biotech first reported a position in GILD in Q2 2013 and has held it in 24 quarters since. The position peaked at $318M in Q2 2015. 1,492 funds tracked by Wall St. Rank hold GILD as of Q1 2019.

  • BB Biotech held 1,142,204 shares of Gilead Sciences worth $74.3M as of Q1 2019.
  • BB Biotech sold 190,000 Gilead Sciences shares in Q1 2019, an estimated $12.6M.
  • Gilead Sciences made up 1.87% of BB Biotech's portfolio in Q1 2019, its #17 holding.
  • BB Biotech first reported a position in Gilead Sciences in Q2 2013 and has held it in 24 quarters since.
  • BB Biotech's Gilead Sciences position peaked at $318M in Q2 2015.
  • 1,492 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.